vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and Coherus Oncology, Inc. (CHRS). Click either name above to swap in a different company.
Arteris, Inc. is the larger business by last-quarter revenue ($20.1M vs $12.7M, roughly 1.6× Coherus Oncology, Inc.). Arteris, Inc. runs the higher net margin — -42.2% vs -295.3%, a 253.1% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs 30.0%). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs -47.0%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
AIP vs CHRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $12.7M |
| Net Profit | $-8.5M | $-37.6M |
| Gross Margin | 90.8% | 68.3% |
| Operating Margin | -42.0% | -359.9% |
| Net Margin | -42.2% | -295.3% |
| Revenue YoY | 30.0% | 64.9% |
| Net Profit YoY | -3.7% | 25.7% |
| EPS (diluted) | $-0.19 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $12.7M | ||
| Q3 25 | $17.4M | $11.6M | ||
| Q2 25 | $16.5M | $10.3M | ||
| Q1 25 | $16.5M | — | ||
| Q4 24 | $15.5M | — | ||
| Q3 24 | $14.7M | — | ||
| Q2 24 | $14.6M | $10.3M | ||
| Q1 24 | $12.9M | — |
| Q4 25 | $-8.5M | $-37.6M | ||
| Q3 25 | $-9.0M | $-35.5M | ||
| Q2 25 | $-9.1M | $297.8M | ||
| Q1 25 | $-8.1M | — | ||
| Q4 24 | $-8.2M | — | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $-8.3M | $-12.9M | ||
| Q1 24 | $-9.4M | — |
| Q4 25 | 90.8% | 68.3% | ||
| Q3 25 | 89.9% | 67.8% | ||
| Q2 25 | 89.4% | 66.9% | ||
| Q1 25 | 90.8% | — | ||
| Q4 24 | 89.8% | — | ||
| Q3 24 | 90.1% | — | ||
| Q2 24 | 90.0% | 82.4% | ||
| Q1 24 | 88.7% | — |
| Q4 25 | -42.0% | -359.9% | ||
| Q3 25 | -50.1% | -383.1% | ||
| Q2 25 | -50.0% | -443.6% | ||
| Q1 25 | -46.6% | — | ||
| Q4 24 | -45.9% | — | ||
| Q3 24 | -53.8% | — | ||
| Q2 24 | -51.1% | -384.9% | ||
| Q1 24 | -70.5% | — |
| Q4 25 | -42.2% | -295.3% | ||
| Q3 25 | -51.6% | -307.1% | ||
| Q2 25 | -55.3% | 2903.9% | ||
| Q1 25 | -49.1% | — | ||
| Q4 24 | -53.0% | — | ||
| Q3 24 | -52.2% | — | ||
| Q2 24 | -57.2% | -125.5% | ||
| Q1 24 | -72.6% | — |
| Q4 25 | $-0.19 | $-0.34 | ||
| Q3 25 | $-0.21 | $-0.31 | ||
| Q2 25 | $-0.22 | $2.57 | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.19 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.22 | $-0.11 | ||
| Q1 24 | $-0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $172.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-14.6M | $61.0M |
| Total Assets | $115.0M | $258.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $172.1M | ||
| Q3 25 | $39.0M | $191.7M | ||
| Q2 25 | $38.0M | $237.6M | ||
| Q1 25 | $42.3M | — | ||
| Q4 24 | $43.8M | — | ||
| Q3 24 | $48.7M | — | ||
| Q2 24 | $45.8M | $159.2M | ||
| Q1 24 | $44.8M | — |
| Q4 25 | $-14.6M | $61.0M | ||
| Q3 25 | $-11.4M | $87.8M | ||
| Q2 25 | $-7.5M | $119.8M | ||
| Q1 25 | $-4.8M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $5.3M | $-84.1M | ||
| Q1 24 | $9.5M | — |
| Q4 25 | $115.0M | $258.3M | ||
| Q3 25 | $107.7M | $516.5M | ||
| Q2 25 | $106.9M | $439.5M | ||
| Q1 25 | $98.3M | — | ||
| Q4 24 | $106.1M | — | ||
| Q3 24 | $97.7M | — | ||
| Q2 24 | $96.4M | $674.9M | ||
| Q1 24 | $101.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-19.7M |
| Free Cash FlowOCF − Capex | $3.0M | — |
| FCF MarginFCF / Revenue | 15.1% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-19.7M | ||
| Q3 25 | $3.2M | $-46.3M | ||
| Q2 25 | $-2.5M | $-46.6M | ||
| Q1 25 | $2.9M | — | ||
| Q4 24 | $-2.6M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $311.0K | $59.7M | ||
| Q1 24 | $477.0K | — |
| Q4 25 | $3.0M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-2.8M | — | ||
| Q1 25 | $2.7M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $264.0K | — | ||
| Q1 24 | $281.0K | — |
| Q4 25 | 15.1% | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | -17.2% | — | ||
| Q1 25 | 16.2% | — | ||
| Q4 24 | -17.3% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
